Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
Posted inIOncology

ASCO International Perspectives | Professor Thomas Powles: Rapid Advances in Targeted and Immunotherapy – EV and Durvalumab-Based Regimens Improve Survival in Urothelial Carcinoma Patients

Posted by By Artie Zou (Lili Zou） 2025.06.30Posted inIOncology0 Shares
Home » ASCO International Perspectives | Professor Thomas Powles: Rapid Advances in Targeted and Immunotherapy – EV and Durvalumab-Based Regimens Improve Survival in Urothelial Carcinoma Patients
YouTube player
Post Views: 3,419

Share via:

  • Facebook
  • X (Twitter)
  • LinkedIn
  • More
Last updated on 2025.08.14
Artie Zou (Lili Zou）
View All Posts

Post navigation

Previous Post
PI Panel: Integrating Eastern and Western Perspectives — Future Innovations in Esophageal Cancer Management PI Panel: Integrating Eastern and Western Perspectives — Future Innovations in Esophageal Cancer Management
Next Post
ASCO 2025 Researcher Insights | Prof. Dickon Hayne Presents ANZUP 1301 Study Addressing the Global BCG Shortage
  • LinkedIn
  • Twitter
  • Mail
Related Media:
Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
Media Medic Publishing Company Limited(HK)
赛美出版有限公司（香港）
Scroll to Top
  • Facebook
  • X (Twitter)
  • LinkedIn
  • More Networks
Share via
Facebook
X (Twitter)
LinkedIn
Mix
Email
Print
Copy Link
Copy link
CopyCopied